Becton Dickinson: leaders came and went.
- Industry
- Surgical & Medical Instruments & Apparatus
- Headquarters
- United States
- Ticker
- BDX (NYSE)
- Sources
- SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 8, 2026
- Leaders came and went. Becton Dickinson filed 35 leadership changes since 2016, more than 86% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.1 points against its sector. The news was rarely news.
- Profitable every year. Becton Dickinson made money in each of its last ten fiscal years, from $0.3 billion (fiscal 2018) to $2.1 billion (fiscal 2021).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $12.5 billion | $1 billion | |
| 2017 | $12.1 billion | $1.1 billion | |
| 2018 | $16 billion | $0.3 billion | |
| 2019 | $17.3 billion | $1.2 billion | |
| 2020 | $16.1 billion | $0.9 billion | |
| 2021 | $19.1 billion | $2.1 billion | |
| 2022 | $18.9 billion | $1.8 billion | |
| 2023 | $19.4 billion | $1.5 billion | |
| 2024 | $20.2 billion | $1.7 billion | |
| 2025 | $21.8 billion | $1.7 billion |
As reported in its annual filings. Losses in red.
Has Becton Dickinson had layoffs?
Job cuts, severance and restructuring
None of Becton Dickinson’s annual reports for 2023 to 2025 describes a layoff, workforce reduction or restructuring.
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-09-30 | $526 million | $148 million |
| 2017-09-30 | $85 million | $57 million |
| 2020-09-30 | $84 million | $80 million |
| 2021-09-30 | $44 million | $56 million |
| 2022-09-30 | $123 million | $82 million |
| 2023-09-30 | $239 million | $165 million |
| 2024-09-30 | $387 million | $305 million |
| 2025-09-30 | $275 million | $231 million |
Becton Dickinson has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Becton Dickinson acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Parata Systems“On July 18, 2022, BD completed the acquisition of Parata Systems (“Parata”), an innovative provider of pharmacy automation solutions, for total cash consideration of $1.548 billion.” 10-K for 2023 | acquisition | On July 18, 2022 | — |
Surgical Instrumentation platform“In August 2023, BD completed the sale of the Interventional segment’s Surgical Instrumentation platform pursuant to a definitive agreement that was signed in June 2023.” 10-K for 2023 | divestiture | In August 2023 | — |
Edwards Lifesciences’ Critical Care product group (renamed BD Advanced Patient Monitoring)“On September 3, 2024, BD completed the acquisition of Critical Care, which was renamed as BD Advanced Patient Monitoring.” 10-K for 2024 | acquisition | September 3, 2024 | — |
Edwards Lifesciences’ Critical Care product group“On September 3, 2024, BD completed the acquisition of Edwards Lifesciences’ Critical Care product group, which was renamed as BD Advanced Patient Monitoring.” 10-K for 2025 | acquisition | On September 3, 2024 | — |
Biosciences and Diagnostic Solutions business (combination with Waters Corporation)“On July 13, 2025, BD entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation (“Waters”) in a Reverse Morris Trust (“RMT”) transaction.” 10-K for 2025 | agreed divestiture | On July 13, 2025 | — |
Interventional segment's Surgical Instrumentation platform“BD recognized a pre-tax gain on the sale of approximately $268 million, which was recorded as a component of Other operating expense (income), net in fiscal year 2023.” 10-K for 2025 | divestiture | — | approximately $268 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-09-30 | $0 | $158 million | — |
| 2017-09-30 | $174 million | $165 million | $143 million |
| 2018-09-30 | $15.15 billion | $534 million | $15.22 billion |
| 2019-09-30 | $0 | $477 million | — |
| 2020-09-30 | $164 million | $0 | $117 million |
| 2021-09-30 | $508 million | $0 | $264 million |
| 2022-09-30 | $2.07 billion | $0 | $1.07 billion |
| 2023-09-30 | $0 | $540 million | — |
| 2024-09-30 | $3.92 billion | $0 | $1.83 billion |
| 2025-09-30 | $0 | $0 | $4 million |
Deal filings since 2016
- 2026-05-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-02-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-09-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-07-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-06-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-02-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-01-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-09-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-08-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-02-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-04-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-03-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-06-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-09-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-02-15 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-12-29 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-07-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-05-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-04-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-02-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Becton Dickinson's competitors?
Who Becton Dickinson names
Becton Dickinson’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Becton Dickinson
Companies whose own annual reports name Becton Dickinson as a competitor.
“Some competitors in the market for professional rapid diagnostic products, such as Becton Dickinson, are large companies with substantial resources, while numerous smaller, yet aggressive companies also compete with us, particularly where barriers to entry are low.” 10-K for 2016
“Major competitors in this market include Becton Dickinson, Danaher, Merck KGaA, Qiagen N.V. and Thermo Fisher Scientific.” 10-K for 2025
“In our Diagnostics business, our primary competitors include Roche Diagnostics, Abbott Laboratories and Cepheid in the molecular diagnostics field, and Becton Dickinson in the cytology field, as well as a wide range of diagnostics companies that sell a single or limited number of assays or products in only a specific market segment (i.e., Cytology, Acute Care, or Oncology Services).” 10-K for 2025
“We compete with products and systems marketed by Becton Dickinson ("BD"), Baxter International ("Baxter"), B. Braun Medical, Inc.” 10-K for 2025
“Our principal competitors in this segment include Becton Dickinson, Hartmann, ICU Medical, Medline, Cardinal Health, Fortive, Steris, MDF Instruments, and BSN.” 10-K for 2025
What are Becton Dickinson's subsidiaries?
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| Accuri Cytometers, Inc. | Delaware |
| Adaptec Medical Devices LLC | Delaware |
| Alverix, Inc. | Delaware |
| Augusta Life Sciences Corp. | Delaware |
| Augusta Life Sciences US Holdco I LLC | Delaware |
| Augusta Life Sciences US Holdco II LLC | Delaware |
| Augusta Life Sciences US Opco I LLC | Delaware |
| Augusta Life Sciences US Opco II LLC | Delaware |
| Augusta Life Sciences US Spinco LLC | Delaware |
| Bard Access Systems, Inc. | Utah |
| Bard Acquisition Sub, Inc. | Delaware |
| Bard ASDI, Inc. | New Jersey |
| Bard Brachytherapy, Inc. | Delaware |
| Bard Devices, Inc. | Delaware |
| Bard IP Holdings Inc. | Delaware |
| Bard Healthcare, Inc. | Texas |
| Bard International, Inc. | Delaware |
| Bard MRL Acquisition Corp. | Delaware |
| Bard Peripheral Vascular, Inc. | Arizona |
| BD Nebula US Formco I LLC | Delaware |
| BD Nebula US Formco II LLC | Delaware |
| BD Ventures LLC | New Jersey |
| BDX INO LLC | Delaware |
| Becton Dickinson Biosciences, Systems and Reagents Inc. | California |
| Becton Dickinson Global Holdings I Inc. | Delaware |
| Becton Dickinson Global Holdings IV LLC | Delaware |
| Becton Dickinson Global Holdings VI LLC | Delaware |
| Becton Dickinson Global Holdings VII LLC | Delaware |
| Becton Dickinson Global Holdings VIII LLC | Delaware |
| Becton Dickinson Infusion Therapy Systems Inc. | Delaware |
| Becton Dickinson Korea Holding, Inc. | Delaware |
| Becton Dickinson Malaysia, Inc. | Oregon |
| Becton Dickinson Matrex Holdings, Inc. | Delaware |
| Becton Dickinson Overseas Services Ltd. | Nevada |
| Becton Dickinson Venture LLC | Delaware |
| Bridger Biomed, Inc. | Montana |
| C. R. Bard, Inc. | New Jersey |
| Cardal II, LLC | Delaware |
| CareFusion 213, LLC | Delaware |
| CareFusion 2200, Inc. | Delaware |
| CareFusion 2201, Inc. | Delaware |
| CareFusion 302, LLC | Delaware |
| CareFusion 303, Inc. | Delaware |
| CareFusion Corporation | Delaware |
| CareFusion Manufacturing, LLC | Delaware |
| CareFusion Resources, LLC | Delaware |
| CareFusion Solutions, LLC | Delaware |
| CAS Medical Systems, Inc. | Delaware |
| Cell Analysis Systems, Inc | Illinois |
| Cellular Research, Inc. | Delaware |
| Chudy Group, LLC | Delaware |
| CRISI Medical Systems, Inc. | Delaware |
| Davol Inc. | Delaware |
| DVL Acquisition Sub, Inc. | Delaware |
| Dymax Corporation | Pennsylvania |
| Echo-US LLC | Delaware |
| Enturican, Inc. | Kansas |
| FJ International, Inc. | Oregon |
| FlowCardia, Inc. | Delaware |
| FlowCardia, LLC | Delaware |
| FlowJo LLC | Oregon |
| Franklin Lakes Enterprises, L.L.C. | New Jersey |
| Galatea Surgical, Inc. | Delaware |
| Gesco International, Inc. | Massachusetts |
| Gesco International, LLC | Massachusetts |
| GSL Solutions, Inc. | Washington |
| GSL Holdings, Inc. | Washington |
| HandyLab, Inc. | Delaware |
| IBD Holdings LLC | Delaware |
| Iontophoretics Corporation | Utah |
| JoHome LLC | Oregon |
| Liberator Health and Education Services, Inc. | Florida |
| Liberator Health and Wellness, Inc. | Florida |
| Liberator Medical Holdings, Inc. | Nevada |
| Liberator Medical Supply, Inc. | Florida |
| Loma Vista Medical, Inc. | Delaware |
| Loma Vista Medical, LLC | Delaware |
| Lutonix, Inc. | Delaware |
| Medafor, Inc. | Minnesota |
| MedChem Products, Inc. | Massachusetts |
| Medegen, LLC | California |
| Med-Design Corporation | Delaware |
| Med Design Investment Holdings, Inc. | Delaware |
| Medinservice.com, Inc. | Utah |
| Medivance, Inc. | Delaware |
| Med-Safe Systems, Inc. | California |
| NAT Diagnostics Inc. | Delaware |
| Navarre Biomedical, LLC | Minnesota |
| Navarre Biomedical, Ltd. | Minnesota |
| Neomend, Inc. | Delaware |
| Nirvana Sciences, Inc. | Delaware |
| NOW Medical Distribution, Inc. | Delaware |
| NOW Medical Distribution, LLC | Delaware |
| Omega Biosystems Incorporated | Delaware |
| Parata Systems, LLC | Delaware |
| Pembroke Blocker LLC | Delaware |
| Pembroke Foreign Blocker LLC | Delaware |
| Pembroke Parent LLC | Delaware |
| PharMingen | California |
| ProSeed, Inc. | New Jersey |
| PureWick Corporation | California |
| Roberts Laboratories, Inc. | Arizona |
| Rochester Medical Corporation | Minnesota |
| Safety Syringes Corporation | Utah |
| Safety Syringes, Inc. | California |
| Scanwell Health, Inc. | Delaware |
| SenoRx, Inc. | Delaware |
| SenoRx, LLC | Delaware |
| Shield Healthcare Centers, Inc. | Delaware |
| Sirigen, Inc. | California |
| Specialized Cooperative Corporation | Utah |
| Specialized Health Products International, Inc. | Delaware |
| Specialized Health Products International, LLC | Delaware |
| Specialized Health Products, Inc. | Utah |
| Surgical Site Solutions, Inc. | Wisconsin |
| Synergy Medical USA Inc. | Delaware |
| Targa Buyer, LLC | Delaware |
| Targa International Holdco, Inc. | Delaware |
| Targa Parent Holdings, LLC | Delaware |
| Tepha, Inc. | Delaware |
| Tri-County Medical & Ostomy Supplies, Inc. | Tennessee |
| TriPath Imaging, Inc. | Delaware |
| TVA Medical, Inc. | Delaware |
| Vascular Pathways, Inc. | Delaware |
| Velano Vascular, Inc. | Delaware |
| Venclose, Inc. | Delaware |
| Venetec International, Inc. | Delaware |
| Venetec International, LLC | Delaware |
| Y-Med, Inc. | Delaware |
| Y-Med, LLC | Delaware |
| ZebraSci, Inc. | Delaware |
| Angiomed GmbH & Co. Medizintechnik KG | Germany |
| Augusta Life Sciences Australia Pty Ltd | Australia |
| Augusta Life Sciences Austria GmbH | Austria |
| Augusta Life Sciences B.V. | Netherlands |
| Augusta Life Sciences CanSpin HoldCo ULC | Canada |
| Augusta Life Sciences Colombia S.A.S. | Colombia |
| Augusta Life Sciences Denmark AS | Denmark |
| Augusta Life Sciences France S.A.S. | France |
| Augusta Life Sciences Hong Kong Limited | Hong Kong |
| Augusta Life Sciences Israel Ltd. | Israel |
| Augusta Life Sciences Italy S.r.l. | Italy |
| Augusta Life Sciences Japan G.K. | Japan |
| Augusta Life Sciences New Zealand ULC | New Zealand |
| Augusta Life Sciences Singapore Pte Ltd. | Singapore |
| Augusta Life Sciences Spinco Canada ULC | Canada |
| Augusta Life Sciences Sweden AB | Sweden |
| Augusta LIfe Sciences UK Ltd. | United Kingdom |
| Bard (Thailand) Limited | Thailand |
| Bard Australia Pty. Limited | Australia |
The list is long; these are the first 150 as the company lists them. From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Layoffs, acquisitions, competitors and subsidiaries are read from Becton Dickinson’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2025-11-25.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 59 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (36 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestStratrix Team
Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.
$1,999 a year · $499 a seatWhat is included →New analyses, by email
The defining moves in business, and what they teach, as they publish.